Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens
Open Access
- 1 June 2020
- journal article
- research article
- Published by Informa UK Limited in Immunotherapy
- Vol. 12 (8), 571-576
- https://doi.org/10.2217/imt-2020-0095
Abstract
Aim: There is a critical need for effective therapies that are immediately available to control the spread of COVID-19 disease. Material & methods: Gamunex®-C and Flebogamma® DIF (Grifols) intravenous immunoglobulin (IVIG) products were tested using ELISA techniques for antibodies against several antigens of human common betacoronaviruses that may crossreact with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Results: Both IVIGs showed consistent reactivity to components of the tested viruses. Positive crossreactivity was seen in SARS-CoV, middle east respiratory syndrome-CoV and SARS-CoV-2. For SARS-CoV-2, positive reactivity was observed at IVIG concentrations ranging from 100 μg/ml with Gamunex-C to 1 mg/ml with Flebogamma 5% DIF. Conclusion: Gamunex-C and Flebogamma DIF contain antibodies reacting against SARS-CoV-2 antigens. Studies to confirm the utility of IVIG preparations for COVID-19 management may be warranted.Keywords
This publication has 29 references indexed in Scilit:
- Intravenous immunoglobulin modulates the maturation of TLR 4-primed peripheral blood monocytesClinical Immunology, 2011
- Intravenous Immunoglobulin a Natural Regulator of Immunity and InflammationTransplantation, 2009
- Mechanisms of action of immune globulinClinical and Experimental Immunology, 2009
- Post‐polio syndrome patients treated with intravenous immunoglobulin: a double‐blinded randomized controlled pilot studyEuropean Journal of Neurology, 2007
- Coronavirus HKU1 Infection in the United StatesEmerging Infectious Diseases, 2006
- Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cellsPediatric Allergy and Immunology, 2005
- Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospitalJournal of Antimicrobial Chemotherapy, 2005
- Antigenic Cross‐Reactivity between Severe Acute Respiratory Syndrome–Associated Coronavirus and Human Coronaviruses 229E and OC43The Journal of Infectious Diseases, 2005
- Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with PneumoniaJournal of Virology, 2005
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004